Gilead Sciences Inc. said that its Quad regimen for treating HIV infection met its primary objective in a Phase II study, fueling hopes that the combination pill could diversify the company's pipeline as its blockbuster HIV drugs face a looming patent cliff. (BioWorld Today) Read More
